Research & Development Committee: William Lee, Göran Ando, Gwen Fyfe
Nomination & Compensation Committee: William Burns, William Lee, Göran Ando
Audit & Finance Committee: Petri Vainio, William Burns, Steven Holtzman
About Us (DRAFT)
Our purpose is to transform the lives of people with cancer and other serious diseases by delivering truly innovative therapies.
Our proprietary DARPin® platform allows us to open a novel therapeutic design space and to rapidly deliver innovative therapies.
As our name indicates, collaboration is in our DNA: within our team, with our partners, and with patients and providers. Only by building on deep trust, individual diversity and shared passion can we reach our common goal of surmounting cancer’s toughest challenges.
Our DARPin® platform also embodies this philosophy. Our therapeutic designs are based on teams of DARPin®modules in one drug candidate that work synergistically toward one therapeutic goal.
Our sustainable growth model utilizes the proceeds from our licensed candidates to forward integrate and to repeatedly deliver innovative therapies to patients with the aim of moving the needle of medicine.